PDF(Pubmed)
Abstract：
BACKGROUND: Medication cost conversations occur less frequently than patients prefer, and it is unclear whether patients have positive experiences with them when they do occur.
OBJECTIVE: To describe patients\' experiences discussing their medication costs with their health care team.
METHODS: Cross-sectional survey.
METHODS: Nationally representative survey fielded in the United States in 2022 (response rate = 48.5%).
METHODS: 1020 adults over age 65.
METHODS: Primary measures were adapted from Clinician and Group Consumer Assessment of Healthcare Providers Survey visit survey v4.0 and captured patients\' experiences of medication cost conversations. Additional measures captured patients\' interest in future cost conversations, the type of clinicians with whom they would be comfortable discussing costs, and sociodemographic characteristics.
RESULTS: Among 1020 respondents who discussed medication prices with their health care team, 39.3% were 75 or older and 78.6% were non-Hispanic White. Forty-three percent of respondents indicated that their prior medication cost conversation was not easy to understand; 3% indicated their health care team was not respectful and 26% indicated their health care team was somewhat respectful during their last conversation; 48% indicated that there was not enough time. Those reporting that their prior discussion was not easy to understand or that their clinician was not definitely respectful were less likely to be interested in future discussions. Only 6% and 10% of respondents indicated being comfortable discussing medication prices with financial counselors or social workers, respectively. Few differences in responses were observed by survey participant characteristics.
CONCLUSIONS: This cross-sectional survey of prior experiences may be subject to recall bias.
CONCLUSIONS: Among older adults who engaged in prior medication cost conversations, many report that these conversations are not easy to understand and that almost one-third of clinicians were somewhat or not respectful. Efforts to increase the frequency of medication cost conversations should consider parallel interventions to ensure the discussions are effective at informing prescribing decisions and reducing cost-related medication nonadherence.
OBJECTIVE: To describe patients\' experiences discussing their medication costs with their health care team.
METHODS: Cross-sectional survey.
METHODS: Nationally representative survey fielded in the United States in 2022 (response rate = 48.5%).
METHODS: 1020 adults over age 65.
METHODS: Primary measures were adapted from Clinician and Group Consumer Assessment of Healthcare Providers Survey visit survey v4.0 and captured patients\' experiences of medication cost conversations. Additional measures captured patients\' interest in future cost conversations, the type of clinicians with whom they would be comfortable discussing costs, and sociodemographic characteristics.
RESULTS: Among 1020 respondents who discussed medication prices with their health care team, 39.3% were 75 or older and 78.6% were non-Hispanic White. Forty-three percent of respondents indicated that their prior medication cost conversation was not easy to understand; 3% indicated their health care team was not respectful and 26% indicated their health care team was somewhat respectful during their last conversation; 48% indicated that there was not enough time. Those reporting that their prior discussion was not easy to understand or that their clinician was not definitely respectful were less likely to be interested in future discussions. Only 6% and 10% of respondents indicated being comfortable discussing medication prices with financial counselors or social workers, respectively. Few differences in responses were observed by survey participant characteristics.
CONCLUSIONS: This cross-sectional survey of prior experiences may be subject to recall bias.
CONCLUSIONS: Among older adults who engaged in prior medication cost conversations, many report that these conversations are not easy to understand and that almost one-third of clinicians were somewhat or not respectful. Efforts to increase the frequency of medication cost conversations should consider parallel interventions to ensure the discussions are effective at informing prescribing decisions and reducing cost-related medication nonadherence.
摘要：
背景：药物费用对话的发生频率低于患者的偏好，目前尚不清楚患者在发生时是否对他们有积极的体验。
目的：描述患者与医疗团队讨论药物费用的经历。
方法：横断面调查。
方法：2022年在美国进行了具有全国代表性的调查（回复率=48.5%）。
方法：1020名65岁以上的成年人。
方法：主要措施改编自临床医生和团体消费者对医疗保健提供者的评估调查访视调查v4.0，并捕获患者的药物费用对话经验。额外的措施抓住了患者对未来成本对话的兴趣，与他们讨论费用的临床医生的类型，和社会人口特征。
结果：在与医疗保健团队讨论药物价格的1020名受访者中，39.3％为75岁或以上，78.6％为非西班牙裔白人。43％的受访者表示他们之前的药物费用对话不容易理解;3％表示他们的医疗保健团队不尊重，26％表示他们的医疗保健团队在最后一次对话中有些尊重;48％表示没有足够的时间。那些报告他们先前的讨论不容易理解或他们的临床医生不一定尊重的人不太可能对未来的讨论感兴趣。只有6%和10%的受访者表示愿意与财务顾问或社会工作者讨论药物价格，分别。通过调查参与者的特征，几乎没有观察到反应的差异。
结论：对先前经验的横断面调查可能会受到回忆偏差的影响。
结论：在以前参与药物费用对话的老年人中，许多报告说，这些对话不容易理解，近三分之一的临床医生有点或不尊重。增加药物成本对话频率的努力应考虑并行干预措施，以确保讨论有效地告知处方决策并减少与成本相关的药物不依从性。
目的：描述患者与医疗团队讨论药物费用的经历。
方法：横断面调查。
方法：2022年在美国进行了具有全国代表性的调查（回复率=48.5%）。
方法：1020名65岁以上的成年人。
方法：主要措施改编自临床医生和团体消费者对医疗保健提供者的评估调查访视调查v4.0，并捕获患者的药物费用对话经验。额外的措施抓住了患者对未来成本对话的兴趣，与他们讨论费用的临床医生的类型，和社会人口特征。
结果：在与医疗保健团队讨论药物价格的1020名受访者中，39.3％为75岁或以上，78.6％为非西班牙裔白人。43％的受访者表示他们之前的药物费用对话不容易理解;3％表示他们的医疗保健团队不尊重，26％表示他们的医疗保健团队在最后一次对话中有些尊重;48％表示没有足够的时间。那些报告他们先前的讨论不容易理解或他们的临床医生不一定尊重的人不太可能对未来的讨论感兴趣。只有6%和10%的受访者表示愿意与财务顾问或社会工作者讨论药物价格，分别。通过调查参与者的特征，几乎没有观察到反应的差异。
结论：对先前经验的横断面调查可能会受到回忆偏差的影响。
结论：在以前参与药物费用对话的老年人中，许多报告说，这些对话不容易理解，近三分之一的临床医生有点或不尊重。增加药物成本对话频率的努力应考虑并行干预措施，以确保讨论有效地告知处方决策并减少与成本相关的药物不依从性。
